论文部分内容阅读
目的对帕金森病患者给予盐酸普拉克索治疗后对其非运动症状改善的情况进行研究和分析。方法 64例原发性帕金森病患者,给予盐酸普拉克索治疗,观察并分析其治疗效果。结果治疗后,患者焦虑及抑郁、认知障碍、幻觉发生率明显低于治疗前,差异具有统计学意义(χ~2=4.664、5.680、7.904,P<0.05)。治疗后患者肢体疼痛、肢体痉挛、不宁腿综合征发生率均明显低于治疗前,差异具有统计学意义(χ~2=8.071、4.137、6.950,P<0.05)。治疗后,患者出汗、口干、流涎症状发生率明显低于治疗前,差异具有统计学意义(P<0.05),治疗前后尿频尿急发生率比较,差异无统计学意义(P>0.05)。治疗1年后,患者帕金森病综合评分量表(UPDRS)评分明显低于治疗前,差异具有统计学意义(P<0.05)。结论盐酸普拉克索能够显著改善帕金森病患者的非运动症状,减轻疼痛,改善抑郁焦虑,减少下肢痉挛、不宁腿综合征等发生,显著改善其生活质量,效果明显,值得临床推广。
Objective To study and analyze the improvement of non-motor symptoms in patients with Parkinson’s disease treated with pramipexole hydrochloride. Methods Sixty-four patients with primary Parkinson’s disease were treated with pramipexole hydrochloride. The therapeutic effect was observed and analyzed. Results After treatment, the incidence of anxiety, depression, cognitive impairment and hallucination were significantly lower than those before treatment (χ ~ 2 = 4.664, 5.680, 7.904, P <0.05). After treatment, the incidence of limb pain, limb spasms and restless legs syndrome were significantly lower than before treatment (χ ~ 2 = 8.071, 4.137, 6.950, P <0.05). After treatment, the incidences of symptoms of sweating, dry mouth and salivation were significantly lower than those before treatment (P <0.05). There was no significant difference in urinary frequency and urgency before and after treatment (P> 0.05) . After 1 year of treatment, the UPDRS scores of patients with Parkinson’s disease were significantly lower than those before treatment, the difference was statistically significant (P <0.05). Conclusions Pramipexole hydrochloride can significantly improve non-motor symptoms, relieve pain, improve depression and anxiety, reduce spasticity of lower extremities and restless legs syndrome in patients with Parkinson’s disease, significantly improve the quality of life, and have a good effect. It is worthy of clinical promotion.